$0.59 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest



Solid Biosciences Inc. is a life science company. The Company is focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Its lead program, SGT-001, is a gene transfer candidate under investigation for its ability to drive functional dystrophin protein expression in patient’s muscles and improve the course of the disease. SGT-001 is designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. Its SGT-001 vector is derived from a non-pathogenic virus called adeno-associated virus (AAV), which was selected for its ability to enter skeletal, diaphragm and cardiac muscle tissues. The vector is designed to carry a synthetic dystrophin transgene construct, called microdystrophin, that retains the components of the dystrophin gene to fit within AAV packaging constraints.

Stock Analysis

last close $0.59
1-mo return -8.4%
3-mo return -31.1%
avg daily vol. 662.6T
52-week high 4.92
52-week low 0.42
market cap. $62M
forward pe -
annual div. -
roe -36.8%
ltg forecast -
dividend yield -
annual rev. $12M
inst own. 62%

Subscribe now for daily local and international financial news